154 related articles for article (PubMed ID: 35286279)
1. Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study.
Kim M; Kim H; Park S; Joo J; Kim IJ; Kim BH
Eur J Endocrinol; 2022 Apr; 186(5):561-571. PubMed ID: 35286279
[TBL] [Abstract][Full Text] [Related]
2. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
3. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
5. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
7. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
[TBL] [Abstract][Full Text] [Related]
8. Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
Pasqual E; Schonfeld S; Morton LM; Villoing D; Lee C; Berrington de Gonzalez A; Kitahara CM
J Clin Oncol; 2022 May; 40(13):1439-1449. PubMed ID: 35044839
[TBL] [Abstract][Full Text] [Related]
9. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancies following thyroid cancer: a population-based study in Taiwan.
Lu CH; Lee KD; Chen PT; Chen CC; Kuan FC; Huang CE; Chen MF; Chen MC
Eur J Endocrinol; 2013 Nov; 169(5):577-85. PubMed ID: 23939917
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.
Hakala TT; Sand JA; Jukkola A; Huhtala HS; Metso S; Kellokumpu-Lehtinen PL
Int J Clin Oncol; 2016 Apr; 21(2):231-239. PubMed ID: 26410770
[TBL] [Abstract][Full Text] [Related]
14. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea.
Seo GH; Cho YY; Chung JH; Kim SW
Thyroid; 2015 Aug; 25(8):927-34. PubMed ID: 26133388
[TBL] [Abstract][Full Text] [Related]
15. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.
Khang AR; Cho SW; Choi HS; Ahn HY; Yoo WS; Kim KW; Kang KW; Yi KH; Park DJ; Lee DS; Chung JK; Cho BY; Park YJ
Clin Endocrinol (Oxf); 2015 Jul; 83(1):117-23. PubMed ID: 25115234
[TBL] [Abstract][Full Text] [Related]
16. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
Wu W; Li S; Xu K; Meng Z
Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer.
Yang J; Wu F; An H; Gan H
Int J Colorectal Dis; 2023 Mar; 38(1):88. PubMed ID: 36995483
[TBL] [Abstract][Full Text] [Related]
18. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.
Subramanian S; Goldstein DP; Parlea L; Thabane L; Ezzat S; Ibrahim-Zada I; Straus S; Brierley JD; Tsang RW; Gafni A; Rotstein L; Sawka AM
Thyroid; 2007 Dec; 17(12):1277-88. PubMed ID: 18020916
[TBL] [Abstract][Full Text] [Related]
19. Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis.
Zhang Y; Liang J; Li H; Cong H; Lin Y
Nucl Med Commun; 2016 Feb; 37(2):110-5. PubMed ID: 26513055
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan.
Lee YT; Liu CJ; Hu YW; Teng CJ; Tzeng CH; Yeh CM; Chen TJ; Lin JK; Lin CC; Lan YT; Wang HS; Yang SH; Jiang JK; Chen WS; Lin TC; Chang SC; Chen MH; Teng HW; Liu JH; Yen CC
Medicine (Baltimore); 2015 Jul; 94(26):e1079. PubMed ID: 26131831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
